Rachael is a writer and environmental consultant who advises nonprofits and foundations on climate change. With an expertise in tropical forests, Rachael has conducted fieldwork in the Brazilian and Ecuadorian Amazon, Borneo, Uganda and elsewhere. After almost a decade in climate policy, Rachael has turned her attention to the spiritual implications of our current ecological crises. Rachael stumbled into psychedelics as a participant in a psilocybin clinical trial for major depression. Her writing excavates the potential risks, rewards, and societal implications of medicalizing and commercializing mysticism. Her work interrogates the intersection of the mystical and the moral, and envisions the role of non-ordinary states of consciousness in current and future forms of religion. Rachael explores these themes as a Junior Fellow at Harvard University's Center for the Study of World Religions.
April 28, 2023
This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.
May 3, 2023
Psymposia’s investigation into the Church of Psilomethoxin (CoP) turns to the Church’s claims that it’s currently “scientifically impossible” to test for psilomethoxin. Psychedelic chemist David Nichols calls that claim “completely nonsensical and nonscientific.
May 9, 2023
The Church of Psilomethoxin now admits that its claims about psilomethoxin are solely based on faith. But how strong are the religious convictions of the Church?
May 15, 2023
The Church of Psilomethoxin claims it’s the victim of “psychedelic capitalism,” but almost everything it claims is wrong.
June 6, 2023
In order to present at Psychedelic Science 2023, speakers must agree to two out-of-the-ordinary requests about content exclusivity and MAPS’ reputation.
June 21, 2023
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.
July 11, 2024
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.